The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.
Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...
In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...
Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful Reduction ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...
Detailed price information for Medicus Pharma Ltd (MDCX-Q) from The Globe and Mail including charting and trades.
Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.
Zacks Investment Research on MSN
AMGN's subcutaneous Tepezza scores phase III win in thyroid eye disease
Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) ...
I felt like I was gonna pass out. I felt a little dizzy. And it leaks for, like, five days,” Cardi B has said of the ...
Bosaya™ and Aukelso™ (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designationPotential benefit to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results